EXTENDED REPORT

Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis

J Vencovsk, S Macháek, L edová, J Kafková, J Gatterová, V Peáková, Riková

Institute of Rheumatology, Prague, Czech Republic

Correspondence to:
Correspondence to:
Dr J Vencovsk, Institute of Rheumatology, Na Slupi 4, 12850 Praha 2, Czech Republic;
venc{at}revma.cz

Objective: To evaluate a contribution of selected laboratory parameters for a prediction of progressive and erosive development in patients with early rheumatoid arthritis (RA).

Methods: In a prospective study baseline levels of antibodies to cyclic citrullinated peptide (anti-CCP), IgM, IgA, and IgG rheumatoid factors (RFs) were measured by enzyme linked immunosorbent assay (ELISA) in 104 patients with RA with disease duration <2 years. Antikeratin antibodies (AKA) and antiperinuclear factor (APF) were detected by indirect immunofluorescence. Patients were divided into two groups based either on the presence or absence of erosions or according to progression of Larsen score at the end of the 24 months’ follow up.

Results: Sixty seven (64%) patients developed radiographic erosions, 49 (47%) had progression in Larsen score, and 36 (35%) progressed by more than 10 Larsen units. Significant differences in erosions and progression between the two groups were detected for anti-CCP, AKA, APF, IgM RF, IgA RF, and IgG RF. Baseline Larsen score correlated significantly with anti-CCP, IgM RF, and IgA RF levels, and all measured antibodies correlated with the progression >10 units. The combination of anti-CCP and IgM RF increased the ability to predict erosive and progressive disease.

Conclusion: The data confirmed that measurement of anti-CCP, AKA, APF, and individual isotypes of RFs was useful for prediction of structural damage early in the disease course. Combined analysis of anti-CCP and IgM RF provides the most accurate prediction.

Keywords: early rheumatoid arthritis; anti-cyclic citrullinated peptide; antikeratin antibodies; antiperinuclear factor; rheumatoid factors

Abbreviations: AKA, antikeratin antibodies; APF, antiperinuclear factor; CCP, cyclic citrullinated peptide; ELISA, enzyme linked immunosorbent assay; PBS, phosphate buffered saline; RA, rheumatoid arthritis; RF, rheumatoid factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• RENESES, S., GONZALEZ-ESCRIBANO, M. F., FERNANDEZ-SUAREZ, A., PESTANA, L., DAVILA, B., WICHMANN, I., GARCIA, A. (2009). The Value of HLA-DRB1 Shared Epitope, -308 Tumor Necrosis Factor-{alpha} Gene Promoter Polymorphism, Rheumatoid Factor, Anti-Citrullinated Peptide Antibodies, and Early Erosions for Predicting Radiological Outcome in Recent-Onset Rheumatoid Arthritis. The Journal of Rheumatology 36: 1143-1149 [Abstract] [Full Text]  
• Labrador-Horrillo, M., Martinez, M{a} A., Selva-O'Callaghan, A., Delgado, J. F., Martinez-Gomez, X., Trallero-Araguas, E., Rodriguez-Sanchez, J. L., Vilardell-Tarres, M. (2009). Anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) 48: 676-679 [Abstract] [Full Text]  
• MENARD, H. A. (2009). Anti-Cyclic Citrullinated Peptide in Preclinical Rheumatoid Arthritis. Food for Thought. The Journal of Rheumatology 36: 663-664 [Full Text]  
• Lee, D M, Phillips, R, Hagan, E M, Chibnik, L B, Costenbader, K H, Schur, P H (2009). Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis. Ann Rheum Dis 68: 201-208 [Abstract] [Full Text]  
• Liao, K P, Batra, K L, Chibnik, L, Schur, P H, Costenbader, K H (2008). Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis 67: 1557-1561 [Abstract] [Full Text]  
• Nishimoto, K, Ikari, K, Mochizuki, T, Tomatsu, T, Toyama, Y, Hara, M, Yamanaka, H, Kamatani, N, Momohara, S (2008). Lack of association between PADI4 and functional severity in Japanese rheumatoid arthritis patients. Ann Rheum Dis 67: 431-432 [Full Text]  
• Nishimura, K., Sugiyama, D., Kogata, Y., Tsuji, G., Nakazawa, T., Kawano, S., Saigo, K., Morinobu, A., Koshiba, M., Kuntz, K. M., Kamae, I., Kumagai, S. (2007). Meta-analysis: Diagnostic Accuracy of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor for Rheumatoid Arthritis. ANN INTERN MED 146: 797-808 [Abstract] [Full Text]  
• Niewold, T.B., Harrison, M.J., Paget, S.A. (2007). Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM 100: 193-201 [Abstract] [Full Text]  
• Vannini, A, Cheung, K, Fusconi, M, Stammen-Vogelzangs, J, Drenth, J P H, Dall'Aglio, A C, Bianchi, F B, Bakker-Jonges, L E, van Venrooij, W J, Pruijn, G J M, Zendman, A J W (2007). Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not?. Ann Rheum Dis 66: 511-516 [Abstract] [Full Text]  
• Bobbio-Pallavicini, F., Caporali, R., Alpini, C., Avalle, S., Epis, O. M, Klersy, C., Montecucco, C. (2007). High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor {alpha} inhibitors in rheumatoid arthritis. Ann Rheum Dis 66: 302-307 [Abstract] [Full Text]  
• Combe, B, Landewe, R, Lukas, C, Bolosiu, H D, Breedveld, F, Dougados, M, Emery, P, Ferraccioli, G, Hazes, J M W, Klareskog, L, Machold, K, Martin-Mola, E, Nielsen, H, Silman, A, Smolen, J, Yazici, H (2007). EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66: 34-45 [Abstract] [Full Text]  
• Avouac, J, Gossec, L, Dougados, M (2006). Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65: 845-851 [Abstract] [Full Text]  
• Yazdani-Biuki, B, Stadlmaier, E, Mulabecirovic, A, Brezinschek, R, Tilz, G, Demel, U, Mueller, T, Brickmann, K, Graninger, W B, Brezinschek, H-P (2005). Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 64: 1224-1226 [Abstract] [Full Text]  
• Nielen, M M J, van der Horst, A R, van Schaardenburg, D, van der Horst-Bruinsma, I E, van de Stadt, R J, Aarden, L, Dijkmans, B A C, Hamann, D (2005). Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 64: 1199-1204 [Abstract] [Full Text]  
• Chapuy-Regaud, S., Sebbag, M., Baeten, D., Clavel, C., Foulquier, C., De Keyser, F., Serre, G. (2005). Fibrin Deimination in Synovial Tissue Is Not Specific for Rheumatoid Arthritis but Commonly Occurs during Synovitides. J. Immunol. 174: 5057-5064 [Abstract] [Full Text]  
• Caponi, L, Petit-Teixeira, E, Sebbag, M, Bongiorni, F, Moscato, S, Pratesi, F, Pierlot, C, Osorio, J, Chapuy-Regaud, S, Guerrin, M, Cornelis, F, Serre, G, Migliorini, P, for ECRAF, (2005). A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann Rheum Dis 64: 587-593 [Abstract] [Full Text]  
• Lindqvist, E, Eberhardt, K, Bendtzen, K, Heinegard, D, Saxne, T (2005). Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64: 196-201 [Abstract] [Full Text]  
• Kamoun, M. (2005). Diagnostic Performance and Predictive Value of Anti-citrullinated Peptide Antibodies for Diagnosis of Rheumatoid Arthritis: Toward More Accurate Detection?. Clin. Chem. 51: 12-13 [Full Text]  
• van Holten, J, Pavelka, K, Vencovsky, J, Stahl, H, Rozman, B, Genovese, M, Kivitz, A J, Alvaro, J, Nuki, G, Furst, D E, Herrero-Beaumont, G, McInnes, I B, Musikic, P, Tak, P P (2005). A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis 64: 64-69 [Abstract] [Full Text]  
• Gottenberg, J-E, Mignot, S, Nicaise-Rolland, P, Cohen-Solal, J, Aucouturier, F, Goetz, J, Labarre, C, Meyer, O, Sibilia, J, Mariette, X (2005). Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis 64: 114-117 [Abstract] [Full Text]  
• Chang, X., Yamada, R., Suzuki, A., Sawada, T., Yoshino, S., Tokuhiro, S., Yamamoto, K. (2005). Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 44: 40-50 [Abstract] [Full Text]  
• De Rycke, L, Peene, I, Hoffman, I E A, Kruithof, E, Union, A, Meheus, L, Lebeer, K, Wyns, B, Vincent, C, Mielants, H, Boullart, L, Serre, G, Veys, E M, De Keyser, F (2004). Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 63: 1587-1593 [Abstract] [Full Text]  
• Vallbracht, I, Rieber, J, Oppermann, M, Forger, F, Siebert, U, Helmke, K (2004). Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63: 1079-1084 [Abstract] [Full Text]  
• Kastbom, A, Strandberg, G, Lindroos, A, Skogh, T (2004). Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63: 1085-1089 [Abstract] [Full Text]  
• Forslind, K, Ahlmen, M, Eberhardt, K, Hafstrom, I, Svensson, B (2004). Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63: 1090-1095 [Abstract] [Full Text]  
• Vossenaar, E R, Radstake, T R D, van der Heijden, A, van Mansum, M A M, Dieteren, C, de Rooij, D-J, Barrera, P, Zendman, A J W, van Venrooij, W J (2004). Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 63: 373-381 [Abstract] [Full Text]